Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CMA1 | P23946 | 14/20 | 0.48 |
| ▸ | CTRC | Q99895 | 5/20 | 0.48 |
| ▸ | MDM2 | Q00987 | 1/20 | 0.44 |
| ▸ | GSTP1 | P09211 | 1/20 | 0.44 |
| ▸ | PARP10 | Q53GL7 | 1/20 | 0.44 |
| ▸ | XDH | P47989 | 1/20 | 0.44 |
| ▸ | ELANE | P08246 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6805699 | 0.88 | CMA1 (0.52) | CMA1CTRC | |
| SCHEMBL6239360 | 0.85 | CMA1 (0.53) | CMA1CTRCELANE | |
| Hydrochloric Acid SCHEMBL6805327 | 0.84 | CMA1 (0.53) | CMA1CTRCELANE | |
| SCHEMBL6804111 | 0.84 | CMA1 (0.53) | CMA1CTRCELANE | |
| SCHEMBL6805368 | 0.83 | ELANE (0.53) | CMA1CTRCELANE | |
| SCHEMBL6803676 | 0.81 | RAB9A (0.52) | ELANE | |
| SCHEMBL6804071 | 0.80 | ELANE (0.50) | CMA1CTRCELANE | |
| SCHEMBL6799136 | 0.79 | ELANE (0.47) | CMA1CTRCELANE | |
| SCHEMBL6802606 | 0.79 | ELANE (0.47) | CMA1CTRCELANE | |
| SCHEMBL6804320 | 0.75 | ELANE (0.44) | CMA1CTRCELANE |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20040063936-A1 | Pyrimidine derivatives and process for preparing the same | ONO PHARMACEUTICAL CO., LTD. (JP) | 2004-04-01 | — | — | US | claimed |
| EP-1346985-A1 | PYRIMIDINE DERIVATIVES AND PROCESS FOR PREPARING THE SAME | ONO PHARMACEUTICAL CO., LTD. (JP) | 2003-09-24 | — | — | EP | claimed |
| US-20040063936-A1 | Pyrimidine derivatives and process for preparing the same | ONO PHARMACEUTICAL CO., LTD. (JP) | 2004-04-01 | — | — | US | disclosed |
| EP-1346985-A1 | PYRIMIDINE DERIVATIVES AND PROCESS FOR PREPARING THE SAME | ONO PHARMACEUTICAL CO., LTD. (JP) | 2003-09-24 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040063936-A1 | Pyrimidine derivatives and process for preparing the same | DPYD, NUDT1, UMPS | CMA1 1079/4885CTRC 2595/4885MDM2 3192/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.